The Paris-based biotech is posting a sharp decline on Monday in a nearly stable Paris market, bringing its monthly loss to over 13%. The stock, which had regained momentum over the summer thanks to regulatory advances, is now under pressure, with a symbolic level within reach.
Abivax below its three moving averages, the 100 € threshold under pressure
In trading, Abivax falls 2.75% to 99.00 €, ranking among the steepest declines on the SBF 120. The stock is settling below the 100 € mark for the first time, which coincides with the support threshold identified at 100.20 €. This downside breach is notable: over one month, the decline reaches 13.54%, partially offsetting the summer rebound. The technical configuration has deteriorated significantly.
The price is now trading below its three moving averages: MA20 at 107.42 €, MA50 at 107.37 € and MA200 at 102.95 €, with respective gaps of nearly 8% for the first two and 3.84% for the third. The RSI at 41 remains in neutral territory, without a clear signal of selling exhaustion, which keeps the downward pressure intact in the short term. Monthly volatility, at 25.51%, reflects the amplitude of movements that characterize this type of biotechnology stock.
Encouraging FDA advances, but sustained short interest in the capital
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On the fundamentals, Abivax is nevertheless posting a gain of nearly 49% over one year, driven in particular by the positive FDA feedback received in early August as part of pre-NDA discussions on obefazimod, its flagship therapeutic candidate for ulcerative colitis. The company targeted, when publishing its results on June 29, 2026, the submission of the marketing authorization request in the United States by year-end. This regulatory timeline remains the main substantive issue for the stock. In parallel, declared net short positions reach 5.04% of the capital, held by five funds, according to the filings reviewed.
This level, up slightly by 0.16 percentage points over thirty days compared to the 4.88% recorded a month earlier, reflects a persistent bearish bet on the stock. A short interest of this magnitude on a biotech in regulatory phase generally translates into heightened sensitivity to authorization process risks, without being able to infer lasting distrust: short positions can be covered quickly in the event of favorable news. The next resistance is identified at 120.10 €, representing an upside potential of over 21% from the current price.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 3T 2025
Guidance from the release
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
